| Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue? | 11/01 10:16 | zacks.com |
| Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett's Esophagus Patients | 10/29 16:30 | businesswire.com |
| Castle Biosciences to Participate in Upcoming Investor Conferences | 10/28 07:00 | businesswire.com |
| Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going | 10/23 09:51 | zacks.com |
| Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy? | 10/22 13:06 | zacks.com |
| Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors | 10/20 05:00 | businesswire.com |
| Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential | 10/16 07:00 | businesswire.com |
| Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out? | 10/15 10:22 | zacks.com |
| Strength Seen in Castle Biosciences (CSTL): Can Its 9.4% Jump Turn into More Strength? | 10/15 05:51 | zacks.com |
| Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024 | 10/14 07:00 | businesswire.com |